Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more
Anixa Biosciences Inc (ANIX) - Net Assets
Latest net assets as of January 2026: $13.85 Million USD
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has net assets worth $13.85 Million USD as of January 2026.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.23 Million) and total liabilities ($1.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.85 Million |
| % of Total Assets | 90.89% |
| Annual Growth Rate | 3.83% |
| 5-Year Change | -59.88% |
| 10-Year Change | 1312.69% |
| Growth Volatility | 138.34 |
Anixa Biosciences Inc - Net Assets Trend (1985–2025)
This chart illustrates how Anixa Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anixa Biosciences Inc (1985–2025)
The table below shows the annual net assets of Anixa Biosciences Inc from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | $13.95 Million | -26.14% |
| 2024-10-31 | $18.89 Million | -19.18% |
| 2023-10-31 | $23.37 Million | -17.12% |
| 2022-10-31 | $28.20 Million | -18.89% |
| 2021-10-31 | $34.77 Million | +320.68% |
| 2020-10-31 | $8.26 Million | +71.73% |
| 2019-10-31 | $4.81 Million | -7.16% |
| 2018-10-31 | $5.18 Million | -34.58% |
| 2017-10-31 | $7.92 Million | +702.34% |
| 2016-10-31 | $987.48K | -80.46% |
| 2015-10-31 | $5.05 Million | +26.04% |
| 2014-10-31 | $4.01 Million | +220.75% |
| 2013-10-31 | $-3.32 Million | -178.09% |
| 2012-10-31 | $-1.19 Million | -212.86% |
| 2011-10-31 | $1.06 Million | -76.98% |
| 2010-10-31 | $4.60 Million | +3.23% |
| 2009-10-31 | $4.45 Million | +157.32% |
| 2008-10-31 | $1.73 Million | +45.24% |
| 2007-10-31 | $1.19 Million | -7.06% |
| 2006-10-31 | $1.28 Million | +14.65% |
| 2005-10-31 | $1.12 Million | -40.31% |
| 2004-10-31 | $1.87 Million | -5.80% |
| 2003-10-31 | $1.99 Million | -14.21% |
| 2002-10-31 | $2.32 Million | -44.38% |
| 2001-10-31 | $4.17 Million | -25.03% |
| 2000-10-31 | $5.56 Million | -11.78% |
| 1999-10-31 | $6.30 Million | -47.06% |
| 1998-10-31 | $11.90 Million | -36.70% |
| 1997-10-31 | $18.80 Million | -17.54% |
| 1996-10-31 | $22.80 Million | +142.55% |
| 1995-10-31 | $9.40 Million | +46.88% |
| 1994-10-31 | $6.40 Million | -21.95% |
| 1993-10-31 | $8.20 Million | +100.00% |
| 1992-10-31 | $4.10 Million | -2.38% |
| 1991-10-31 | $4.20 Million | +2.44% |
| 1990-10-31 | $4.10 Million | 0.00% |
| 1989-10-31 | $4.10 Million | +105.00% |
| 1988-10-31 | $2.00 Million | +81.82% |
| 1987-10-31 | $1.10 Million | -15.38% |
| 1986-10-31 | $1.30 Million | -58.06% |
| 1985-10-31 | $3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anixa Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24737700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $330.00K | 2.18% |
| Other Components | $266.51 Million | 1757.85% |
| Total Equity | $15.16 Million | 100.00% |
Anixa Biosciences Inc Competitors by Market Cap
The table below lists competitors of Anixa Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prairie Operating Co. Common Stock
OTCQB:PROP
|
$87.48 Million |
|
A.L.A. S.P.A. O.N.
F:8WD
|
$87.49 Million |
|
BRIM Biotechnology Inc.
TWO:6885
|
$87.55 Million |
|
RENOLD PLC LS-05
F:7M5
|
$87.58 Million |
|
Accsys Technologies PLC
PINK:ACSYF
|
$87.44 Million |
|
Bansal Wire Industries Ltd
NSE:BANSALWIRE
|
$87.42 Million |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
$87.41 Million |
|
Sonaecom SGPS
LS:SNC
|
$87.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anixa Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,998,000 to 15,161,000, a change of -4,837,000 (-24.2%).
- Net loss of 10,927,000 reduced equity.
- New share issuances of 2,378,000 increased equity.
- Other factors increased equity by 3,712,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.93 Million | -72.07% |
| Share Issuances | $2.38 Million | +15.68% |
| Other Changes | $3.71 Million | +24.48% |
| Total Change | $- | -24.19% |
Book Value vs Market Value Analysis
This analysis compares Anixa Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.34x to 5.93x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-10-31 | $2.07 | $2.77 | x |
| 1986-10-31 | $0.82 | $2.77 | x |
| 1987-10-31 | $0.72 | $2.77 | x |
| 1988-10-31 | $1.52 | $2.77 | x |
| 1989-10-31 | $2.54 | $2.77 | x |
| 1990-10-31 | $2.54 | $2.77 | x |
| 1991-10-31 | $2.21 | $2.77 | x |
| 1992-10-31 | $2.07 | $2.77 | x |
| 1993-10-31 | $4.00 | $2.77 | x |
| 1994-10-31 | $3.00 | $2.77 | x |
| 1995-10-31 | $4.07 | $2.77 | x |
| 1996-10-31 | $9.15 | $2.77 | x |
| 1997-10-31 | $7.42 | $2.77 | x |
| 1998-10-31 | $4.51 | $2.77 | x |
| 1999-10-31 | $2.34 | $2.77 | x |
| 2000-10-31 | $2.03 | $2.77 | x |
| 2001-10-31 | $1.47 | $2.77 | x |
| 2002-10-31 | $0.77 | $2.77 | x |
| 2003-10-31 | $0.60 | $2.77 | x |
| 2004-10-31 | $0.51 | $2.77 | x |
| 2005-10-31 | $0.29 | $2.77 | x |
| 2006-10-31 | $0.31 | $2.77 | x |
| 2007-10-31 | $0.26 | $2.77 | x |
| 2008-10-31 | $0.30 | $2.77 | x |
| 2009-10-31 | $0.73 | $2.77 | x |
| 2010-10-31 | $0.70 | $2.77 | x |
| 2011-10-31 | $0.14 | $2.77 | x |
| 2012-10-31 | $-0.15 | $2.77 | x |
| 2013-10-31 | $-0.38 | $2.77 | x |
| 2014-10-31 | $0.42 | $2.77 | x |
| 2015-10-31 | $0.53 | $2.77 | x |
| 2016-10-31 | $0.11 | $2.77 | x |
| 2017-10-31 | $0.65 | $2.77 | x |
| 2018-10-31 | $0.31 | $2.77 | x |
| 2019-10-31 | $0.26 | $2.77 | x |
| 2020-10-31 | $0.39 | $2.77 | x |
| 2021-10-31 | $1.24 | $2.77 | x |
| 2022-10-31 | $0.96 | $2.77 | x |
| 2023-10-31 | $0.79 | $2.77 | x |
| 2024-10-31 | $0.63 | $2.77 | x |
| 2025-10-31 | $0.47 | $2.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anixa Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-72.07%) is above the historical average (-151.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -54.84% | -566.67% | 0.09x | 1.06x | $-2.01 Million |
| 1986 | -138.46% | -1800.00% | 0.07x | 1.15x | $-1.93 Million |
| 1987 | -127.27% | -1400.00% | 0.08x | 1.09x | $-1.51 Million |
| 1988 | -65.00% | -1300.00% | 0.05x | 1.05x | $-1.50 Million |
| 1989 | -26.83% | -1100.00% | 0.02x | 1.02x | $-1.51 Million |
| 1990 | -26.83% | -1100.00% | 0.02x | 1.02x | $-1.51 Million |
| 1991 | -30.95% | -1300.00% | 0.02x | 1.02x | $-1.72 Million |
| 1992 | -43.90% | -1800.00% | 0.02x | 1.07x | $-2.21 Million |
| 1993 | -34.15% | -2800.00% | 0.01x | 1.06x | $-3.62 Million |
| 1994 | -53.13% | -3400.00% | 0.02x | 1.03x | $-4.04 Million |
| 1995 | -31.91% | -3000.00% | 0.01x | 1.03x | $-3.94 Million |
| 1996 | -23.68% | -5400.00% | 0.00x | 1.08x | $-7.68 Million |
| 1997 | -30.85% | -5800.00% | 0.01x | 1.06x | $-7.68 Million |
| 1998 | -59.66% | -7100.00% | 0.01x | 1.12x | $-8.29 Million |
| 1999 | -134.92% | -8500.00% | 0.01x | 1.29x | $-9.13 Million |
| 2000 | -89.32% | -337.24% | 0.21x | 1.24x | $-5.52 Million |
| 2001 | -85.73% | -211.26% | 0.26x | 1.58x | $-3.99 Million |
| 2002 | -141.76% | -63.34% | 1.90x | 1.18x | $-3.52 Million |
| 2003 | -156.64% | -1275.24% | 0.10x | 1.17x | $-3.31 Million |
| 2004 | -179.43% | -679.66% | 0.21x | 1.24x | $-3.55 Million |
| 2005 | -398.14% | -1012.14% | 0.30x | 1.31x | $-4.56 Million |
| 2006 | -592.97% | -1494.33% | 0.27x | 1.45x | $-7.73 Million |
| 2007 | -458.15% | -1121.12% | 0.26x | 1.57x | $-5.58 Million |
| 2008 | -336.46% | -282.17% | 0.28x | 4.33x | $-5.99 Million |
| 2009 | -370.35% | -1561.76% | 0.11x | 2.21x | $-16.93 Million |
| 2010 | -112.60% | -708.27% | 0.07x | 2.19x | $-5.63 Million |
| 2011 | -697.34% | -735.46% | 0.12x | 8.17x | $-7.48 Million |
| 2012 | 0.00% | -452.42% | 0.17x | 0.00x | $-4.13 Million |
| 2013 | 0.00% | -2592.28% | 0.07x | 0.00x | $-9.75 Million |
| 2014 | -239.58% | -261.94% | 0.40x | 2.26x | $-10.01 Million |
| 2015 | -27.29% | -14.90% | 0.99x | 1.85x | $-1.88 Million |
| 2016 | -508.01% | -1672.14% | 0.05x | 5.70x | $-5.12 Million |
| 2017 | -63.22% | -1381.79% | 0.04x | 1.11x | $-5.80 Million |
| 2018 | -257.53% | -1258.07% | 0.17x | 1.19x | $-14.54 Million |
| 2019 | -222.47% | -4658.82% | 0.04x | 1.20x | $-12.17 Million |
| 2020 | -115.65% | 0.00% | 0.00x | 1.08x | $-11.01 Million |
| 2021 | -36.53% | -2528.64% | 0.01x | 1.02x | $-16.49 Million |
| 2022 | -46.80% | -0.55% | 81.19x | 1.05x | $-16.50 Million |
| 2023 | -40.31% | -4671.90% | 0.01x | 1.05x | $-12.24 Million |
| 2024 | -62.78% | 0.00% | 0.00x | 1.08x | $-14.55 Million |
| 2025 | -72.07% | 0.00% | 0.00x | 1.06x | $-12.44 Million |
Industry Comparison
This section compares Anixa Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | $13.85 Million | -54.84% | 0.10x | $87.46 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |